Psychosis in nursing home patients with Parkinson's disease.
作者： Gail A. Kang , Jeff M. Bronstein
DOI: 10.1016/S1525-8610(04)70110-3
关键词: Nursing homes 、 In patient 、 Psychosis 、 Psychiatry 、 Intensive care medicine 、 Disease 、 Motor symptoms 、 Atypical neuroleptic 、 Medicine 、 Parkinson's disease 、 Cognitive decline
摘要: Psychosis in patients with Parkinson's disease (PD) is a common and important problem. It frequent cause of nursing home placement associated high mortality. The psychosis PD usually multi-factorial but often involves the agents used to treat motor symptoms disease. Treatment strategies should include ruling out other causes cognitive decline, reducing anti-PD medications, judicious use atypical neuroleptic medications. Cholinesterase inhibitors can also be useful as an adjunctive agent decline. Careful management result good control hallucinations delusions without significant decline function.
sci-hub.se 参考文章(59)
Philip Seeman, Atypical Antipsychotics: Mechanism of Action: The Canadian Journal of Psychiatry. ,vol. 47, pp. 27- 38 ,(2002) , 10.1177/070674370204700106
C. Dsouza, B. S. D. Sastry, A. Gupta, M. D. Alldrick, Management of psychosis in Parkinson's disease. International Journal of Clinical Practice. ,vol. 57, pp. 295- 300 ,(2003)
U. K. Rinne, F. Bracco, C. Chouza, E. Dupont, O. Gershanik, J. F. M. Masso, J. L. Montastruc, C. D. Marsden, A. Dubini, N. Orlando, R. Grimaldi, Cabergoline in the treatment of early parkinson's disease: Results of the first year of treatment in a double-blind comparison of cabergoline and levodopa Neurology. ,vol. 48, pp. 363- 368 ,(1997) , 10.1212/WNL.48.2.363
J. Zoldan, G. Friedberg, M. Livneh, E. Melamed, Psychosis in advanced Parkinson's disease: Treatment with ondansetron, a 5‐HT3 receptor antagonist Neurology. ,vol. 45, pp. 1305- 1308 ,(1995) , 10.1212/WNL.45.7.1305
J. M. Rabey, P. Nissipeanu, A. D. Korczyn, Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease Journal of Neural Transmission - Parkinson's Disease and Dementia Section. ,vol. 4, pp. 277- 282 ,(1992) , 10.1007/BF02260076
TORGNY H. SVENSSON, JAN M. MATHÉ, JONAS L. ANDERSSON, BMGEORGE G. NOMIKOS, BENGT E. HILDEBRAND, MONICA MARCUS, Mode of Action of Atypical Neuroleptics in Relation to the Phencyclidine Model of Schizophrenia: Role of 5-HT2 Receptor and α1-Adrenoreceptor Antagonism Journal of Clinical Psychopharmacology. ,vol. 15, ,(1995) , 10.1097/00004714-199502001-00003
P. Tiraboschi, L. A. Hansen, M. Alford, M. N. Sabbagh, B. Schoos, E. Masliah, L. J. Thal, J. Corey-Bloom, Cholinergic dysfunction in diseases with Lewy bodies. Neurology. ,vol. 54, pp. 407- 407 ,(2000) , 10.1212/WNL.54.2.407
Claude-Alain Maurage, Marie-Magdeleine Ruchoux, Rob De Vos, Andrei Surguchov, Alain Destee, Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Annals of Neurology. ,vol. 54, pp. 542- 547 ,(2003) , 10.1002/ANA.10730
Colin Klein, Jacob Gordon, Lea Pollak, J. Martin Rabey, Clozapine in Parkinson's disease psychosis: 5-year follow-up review Clinical Neuropharmacology. ,vol. 26, pp. 8- 11 ,(2003) , 10.1097/00002826-200301000-00003
Jeffrey L. Cummings, Behavioral Complications of Drug Treatment of Parkinson's Disease Journal of the American Geriatrics Society. ,vol. 39, pp. 708- 716 ,(1991) , 10.1111/J.1532-5415.1991.TB03627.X